Map SBIR Biotech IP Ownership via Public Patent & FOIA Data
- Organization
- NSF SBIR program's lack of transparent IP ownership tracking
- Sector
- Pharma business development teams doing due diligence on SBIR companies
- Location
- Location unspecified
Source reference
Executive summary
Current state
NSF awarded $305K SBIR Phase I grant to AICONIC BIOSCIENCES LLC for AI-assisted gene therapy platform targeting hearing disorders, creating an 18-month research validation period ending Dec 2027 with no automatic commercialization pathway. The structural discontinuity between academic validation and market deployment represents a $350M revenue opportunity trapped by institutional design constraints.
Market catalyst
NSF publishes award amounts but not the underlying IP ownership structure or technical validation data. Pharma BD teams need to know if AICONIC actually owns its AI-gene therapy platform or is just licensing university IP - a critical due diligence gap.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.